Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06748105

Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia (DAPACOID)

Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia: Phase II Randomized Clinical Trial

Sponsor: Instituto Mexicano del Seguro Social

Conditions Dapagliflozin (Forxiga) Glucocorticoid Hyperglycaemia

Updated 2 times since 2025 Last updated: Dec 20, 2024 Started: Dec 1, 2024 Primary completion: Dec 1, 2025 Completion: Dec 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Dapagliflozin (Forxiga) and Glucocorticoid, this trial is ongoing. The trial is conducted by Instituto Mexicano del Seguro Social and has accumulated 2 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE2
Jan 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2

First recorded

Dec 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Instituto Mexicano del Seguro Social
Lauro Fabián Amador Medina

Data source: Coordinación de Investigación en Salud, Mexico

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• León, Mexico